NI201700078A - Pirazolpiridinaminas - Google Patents

Pirazolpiridinaminas

Info

Publication number
NI201700078A
NI201700078A NI201700078A NI201700078A NI201700078A NI 201700078 A NI201700078 A NI 201700078A NI 201700078 A NI201700078 A NI 201700078A NI 201700078 A NI201700078 A NI 201700078A NI 201700078 A NI201700078 A NI 201700078A
Authority
NI
Nicaragua
Prior art keywords
compounds
disease
preparing
inflammatory
pyrazolpyridinamines
Prior art date
Application number
NI201700078A
Other languages
English (en)
Inventor
Giese Anja
Klar Ulrich
Graham Keith
Kettschau Georg
Sülzle Detlev
Lienau Philip
Pettersen Kirstin
Lefranc Julien
Schmidt Nicole
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of NI201700078A publication Critical patent/NI201700078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de pirazolpiridinamina sustituida de fórmula general (I) según se los describe y define aquí, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticasy combinaciones que comprenden a dichos compuestos y el uso de dichos compuestos para elaborar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o angiogénesis, enfermedad inflamatoria y enfermedad asociada con dolor inflamatorio, como único agente o en combinación con otros ingredientes activos.
NI201700078A 2014-12-19 2017-06-19 Pirazolpiridinaminas NI201700078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14199096 2014-12-19
EP15187501 2015-09-29

Publications (1)

Publication Number Publication Date
NI201700078A true NI201700078A (es) 2017-09-22

Family

ID=54884024

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700078A NI201700078A (es) 2014-12-19 2017-06-19 Pirazolpiridinaminas

Country Status (27)

Country Link
US (1) US10487092B2 (es)
EP (1) EP3233866B1 (es)
JP (1) JP2018501250A (es)
KR (1) KR20170095985A (es)
CN (1) CN107250138A (es)
AU (1) AU2015366417A1 (es)
BR (1) BR112017013148A2 (es)
CA (1) CA2971242A1 (es)
CL (1) CL2017001615A1 (es)
CO (1) CO2017005968A2 (es)
CR (1) CR20170264A (es)
CU (1) CU20170086A7 (es)
DO (1) DOP2017000146A (es)
EA (1) EA201791363A1 (es)
EC (1) ECSP17038893A (es)
GT (1) GT201700138A (es)
IL (1) IL252686A0 (es)
MX (1) MX2017008161A (es)
NI (1) NI201700078A (es)
PE (1) PE20171104A1 (es)
PH (1) PH12017501133A1 (es)
SG (1) SG11201704916TA (es)
SV (1) SV2017005466A (es)
TN (1) TN2017000258A1 (es)
TW (1) TW201625648A (es)
UY (1) UY36460A (es)
WO (1) WO2016096721A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
WO2017081003A1 (en) * 2015-11-12 2017-05-18 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyridinamines
WO2018152117A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
CN111803476A (zh) * 2020-08-14 2020-10-23 华中科技大学协和深圳医院 芬戈莫德用于抑制革兰阳性细菌活性的用途
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
US20230000986A1 (en) * 2021-07-01 2023-01-05 Board Of Regents, The University Of Texas System Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2530281C (en) 2003-07-24 2013-02-12 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
WO2006023843A2 (en) * 2004-08-20 2006-03-02 Bayer Pharmaceuticals Corporation Novel heterocycles
US8703941B2 (en) * 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
ES2592404T3 (es) * 2012-05-21 2016-11-30 Bayer Pharma Aktiengesellschaft Benzotienopirimidinas sustituidas
JP6234444B2 (ja) * 2012-05-21 2017-11-22 バイエル ファーマ アクチエンゲゼルシャフト チエノピリミジン類
EP2922840B1 (en) * 2012-11-08 2016-12-21 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
WO2014118229A1 (en) * 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof

Also Published As

Publication number Publication date
EA201791363A1 (ru) 2018-01-31
BR112017013148A2 (pt) 2019-11-19
UY36460A (es) 2016-07-29
ECSP17038893A (es) 2017-07-31
SV2017005466A (es) 2018-10-02
CR20170264A (es) 2017-07-21
IL252686A0 (en) 2017-08-31
PE20171104A1 (es) 2017-08-07
CA2971242A1 (en) 2016-06-23
CN107250138A (zh) 2017-10-13
TW201625648A (zh) 2016-07-16
JP2018501250A (ja) 2018-01-18
CL2017001615A1 (es) 2018-03-16
SG11201704916TA (en) 2017-07-28
EP3233866B1 (en) 2021-04-21
CU20170086A7 (es) 2017-11-07
CO2017005968A2 (es) 2017-10-20
EP3233866A1 (en) 2017-10-25
WO2016096721A1 (en) 2016-06-23
DOP2017000146A (es) 2017-07-31
US10487092B2 (en) 2019-11-26
GT201700138A (es) 2018-12-06
AU2015366417A1 (en) 2017-06-29
US20180162877A1 (en) 2018-06-14
MX2017008161A (es) 2017-09-18
KR20170095985A (ko) 2017-08-23
TN2017000258A1 (en) 2018-10-19
PH12017501133A1 (en) 2017-11-27

Similar Documents

Publication Publication Date Title
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
NI201700078A (es) Pirazolpiridinaminas
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
UY33598A (es) Imidazopiridazinas sustituidas
NI201600006A (es) Pirazolo-piridinaminas sustituidas
DOP2014000051A (es) Imidazopiridazinas sustituidas con amino
CR20150455A (es) Imidazopiridazinas sustituidas
DOP2016000253A (es) Nuevos compuestos
UY35848A (es) Tienopirimidinas
UY37577A (es) Dihidroimidazopiridindionas sustituidas
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol
UY34630A (es) Imidazopiridazinas sustituidas con amino
AR094934A1 (es) Imidazopiridazinas sustituidas